CareLit · DOI-Nachweis · Pneumologie
Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study
DOI 10.1055/s-0039-1678065
Bibliografische Angaben
Nachweis in CareLit
Autor:innenDP Carbone, D Morgensztern, S Le Moulec, R Santana-Davila, N Ready, CL Hann, BS Glisson, A Dowlati, CM Rudin, S Lally, S Yalamanchili, J Wolf, R Govindan, B Besse
ZeitschriftPneumologie
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 73
Kernaussage aus der Literatur
Abstract-Vorschau
Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study
Zitieren
Zitierempfehlung
DP Carbone, D Morgensztern, S Le Moulec, R Santana-Davila, N Ready, CL Hann, BS Glisson, A Dowlati, CM Rudin, S Lally, S Yalamanchili, J Wolf, R Govindan, B Besse (2019) Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study. Pneumologie, 73 (S 01 S 01). https://doi.org/10.1055/s-0039-1678065
Mit CareLit weiterarbeiten